A Bi-Adjuvant Senolytic Nanovaccine Modulating Dendritic Cell Senescence Ameliorates Aging-Related Metabolic Dysfunction.

Qingxu Song, Xiaoxue Du, Wenbo Dong, Ying Wang, Xiaojing Wang, Qiliang Yin

Department of Spine Surgery, The First Hospital of Jilin University, Changchun, People's Republic of China.Department of Spine Surgery, The First Hospital of Jilin University, Changchun, People's Republic of China. · pubmed

Paper

Abstract

Senolytic vaccines hold promise for eliminating senescent cells, but their efficacy is limited by poor seno-antigen immunogenicity and age-related dendritic cell (DC) dysfunction. Here, we engineered an active biomaterial-enabled bi-adjuvant senolytic nanovaccine (CK5-GC-NV) by co-assembling CpG oligodeoxynucleotide with a fusion protein of the seno-antigen Gpnmb and a cationic spider silk protein variant (CK5). Beyond antigen delivery, the CK5 scaffold acts as an intrinsic senomodulator associated with the downregulation of mitotic kinases Aurka/b and a concomitant decrease in senescence-associated PI3K/AKT phosphorylation in DCs. This intervention attenuates aged DC phenotypes, restores antigen cross-presentation, and synergizes with CpG to elicit potent cytotoxic T-lymphocyte responses against senescent targets. Across multiple aging mouse models, CK5-GC-NV immunization orchestrated targeted clearance of Gpnmb

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that a bi-adjuvant nanovaccine using a spider silk protein scaffold can reverse dendritic cell senescence and enhance the immune clearance of senescent cells. This is relevant because it addresses a fundamental barrier to senolytic therapies—age-related immune dysfunction—by targeting the root cause of aging (senescent cell accumulation) rather than just treating downstream metabolic symptoms.

Author of this paper? Send a correction.